HCPs pick best pharma in oncology

AstraZeneca has continued its run to take the crown as the new perception leader in oncology, with HCPs ranking it the highest across five categories.

ZoomRx interviewed more than 300 oncologists, with 40 per cent of them in hemato-oncology, on their perception of 19 manufacturers of oncology treatments. The survey measured their perceptions on innovation, patient-centricity, reputation, HCP centricity, and promotional practices, with six countries contributing to the global score. The results were published in the Global Pharma Perception Report Oncology.

It also calculated a net promoter score (NPS) for each company, which is the percentage of the number of respondents with the highest opinion of a pharma minus those with a negative opinion.